ArticleNeurology2020
Return to work following diagnosis of low-grade glioma: A nationwide matched cohort study.
Article in Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Risk factors for return to work in workers who experienced cancer: a systematic review with meta-analysis.Oncology reviews · 2026Pooled it
- Location of incidental and symptomatic LGGs. A review of comparative studies.NeuroImage. Clinical · 2026Pooled it
- EANS-EANO guidelines on the extent of resection in gliomas.Neuro-oncology · 2026Guideline
- Repeated awake surgery and quality of life in patients with diffuse glioma: a systematic review and meta-analysis.Neurosurgical review · 2023Pooled it
- Contribution of cognitive function and fatigue to health-related quality of life in patients withNeuro-oncology practice · 2026Article
- Improving quality of care for patients with high-grade glioma and their informal caregivers: Insights from focus groups with healthcare professionals.Neuro-oncology practice · 2026Article
- Supramaximal resection in gliomas: a narrative review of surgical techniques, clinical outcomes, and ethical considerations.Annals of medicine and surgery (2012) · 2026Review
- Patient Preferences and Treatment Decision Drivers in IDH-Mutant Grade 2 Glioma: An International Discrete Choice Experiment.The patient · 2026Article
- Returning to work after treatment for a low-grade glioma: analysing return-to-work rates and exploring barriers experienced by patients.Journal of neuro-oncology · 2026Article
- Neurosurgery Advancements: From Technical Innovation to Patient-Centered Outcomes-A Narrative Review.Journal of clinical medicine · 2026Review
- Evaluating work activity and societal burden in patients with grade 2 IDH-mutant glioma.Neuro-oncology practice · 2026Article
- Reliable cognitive changes the first year following guideline-based treatment of isocitrate dehydrogenase mutated gliomas: A longitudinal multicenter study.Neuro-oncology · 2026Article
- Tele-cognitive rehabilitation for adult lower-grade glioma: An interim prospective pilot feasibility study.Neuro-oncology practice · 2026Article
- The neuropsychological outcome of patients undergoing intraoperative MRI surgery for insular infiltrating gliomas.Journal of neuro-oncology · 2026Article
- A scoping review: Understanding brain tumor patients' decisional needs and preferences.Neuro-oncology practice · 2025Review
- Estimating Health State Utilities for IDH-Mutant Diffuse Glioma.PharmacoEconomics - open · 2025Article
- A scoping review of proton radiation therapy and mutant-isocitrate dehydrogenase-inhibitors in IDH mutated lower-grade gliomas: pushing beyond surrogate end-points.Acta neurochirurgica · 2025Article
- The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.Neuro-oncology · 2025Review
- Resection Location and Work Resumption in Patients With Lower-Grade Glioma: A Multicenter Cohort Study.Neurosurgery practice · 2025Article
- A thematic analysis of shared decision-making in consultations with patients with a presumed brain tumor and neurosurgeons.Neuro-oncology practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveReturn-to-work (RTW) following diagnosis of infiltrative low-grade gliomas is unknown.
methodsSwedish patients with histopathologic verified WHO grade II diffuse glioma diagnosed between 2005 and 2015 were included. Data were acquired from several Swedish registries. A total of 381 patients aged 18-60 were eligible. A matched control population (n = 1,900) was acquired. Individual data on sick leave, compensations, comorbidity, and treatments assigned were assessed. Predictors were explored using multivariable logistic regression.
resultsOne year before surgery/index date, 88% of cases were working, compared to 91% of controls. The proportion of controls working remained constant, while patients had a rapid increase in sick leave approximately 6 months prior to surgery. After 1 and 2 years, respectively, 52% and 63% of the patients were working. Predictors for no RTW after 1 year were previous sick leave (odds ratio [OR] 0.92, 95% confidence interval [CI] 0.88-0.96,
conclusionsApproximately half of patients RTW within the first year. Lower functional status, previous sick leave, older age, and adjuvant treatment were risk factors for no RTW at 1 year after surgery. Female sex, comorbidity, and biopsy only were also unfavorable for RTW at 2 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.